very nice margin rebound. Suspect foreign sensor volume (e.g. Canada) is being impacted by the strong dollar. The more the orthopedic business begins to comprise total revenues, the more domestic-based the revenue stream will be, leading to a possible expansion in both revenues and margins. The "table is set" in terms of lean efficiency, now they need to drive the top line via orthopedic orders. So the quarter is a bit of a push, but the underlying cost structure, the framework is in place.
but knee replacements are only going to continue to rise, even moreso w/same day procedures now being performed in some cases.
Stock hasn't even had a 10,000 share volume day since late May. It's retail accounts/small investors just throwing in the towel on the market. Many micro caps selling a single digit P/E multiples. Many retail investors simply have never come back after the late 2008/early 2009 Financial Crisis. Those that stayed are exiting now. If oil prices under $50/bbl. and interest rates near zero can't grow the worldwide economy, might as well hold cash. Nevertheless, Healthcare is the one area that should should see spending increases.
From $14 to $9 per share in 3 months and nary a peep from the covering analysts. Come out, come out wherever you are.
and continual as the market is only offering sporadic trading liquidity to the seller. Otherwise you would see a lot more volume. You sell however much you can when you can. Could take a while to exit the position. This stock smells really bad. Something amiss at the company? Where are the analysts?
the stronger dollar is likely going to weigh on companies w/multinational exposure for the next two years.
They are definitely struggling the last couple quarters. Foreign exposure (i.e., adverse impact of a stronger U.S. dollar) has to be an issue although they have not mentioned it. They seem to have plateaued and are stuck at $6 million in quarterly revenues, plus or minus a couple hundred thousand dollars. If they don't get unstuck soon, I'll be moving on to other investment ideas.
The new CEO saved the company. However, he is having difficulty achieving consistent growth. Sometimes that involves a different skill set and a different set of personnel. The company needs to establish a track track record of producing reliable, expertly designed medical devices on time and w/o any flaws or production glitches.
At least something in the sector has been working. Better off sticking with the big players. Anything under $750 million market capitalization is just asking for trouble, illiquidity and inevitable whipsaw action. It's a good way to lose all your money.
Think everyone's figured out there is no dividend this year. If they didn't squander all that money for executive search or overpay for the acquisition, or even if they had earned 15 cents per share, they probably could have paid one. Fiscal 2015 is a minor disaster in every way, including all but one executive leaving the company. Hopefully fiscal 2016 will be better and they can re-institute the dividend. They can't seem to control either their business or their own company internals. It's a complete clusterf&#@.